Phase 1 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed a written consent form agreeing to take part in the trial.
- People who have been confirmed through a tissue or cell sample to have a specific type of solid tumour cancer that has spread to other parts of the body, has come back, or is advanced in the local area.
- People who are willing to provide a redacted (personally identifying information removed) copy of their pathology report.
- People who have received no more than 3 rounds of systemic (whole-body) treatment for their recurring cancer.
- People who are in generally good physical condition (able to carry out normal daily activities with at most minor limitations) and have a life expectancy of at least 3 months.
- People whose cancer can be measured using standard imaging guidelines, with at least one measurable area of disease visible on scans.
- People whose liver, kidneys, and other organs are functioning well enough to safely participate.
- People whose cancer has continued to grow or spread after a previous treatment.
Who may not be able to join:
- People who have brain metastases (cancer that has spread to the brain) that are causing symptoms.
- People who have received systemic (whole-body) cancer treatment within the 3 weeks before starting the trial drug.
- People who have had radiation therapy aimed at curing their cancer within the 4 weeks before starting the trial drug.
- People who have had radiation therapy for pain or symptom relief within the 2 weeks before starting the trial drug.
- People who are pregnant or currently breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 617-207-8979
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose Escalation; Dose Expansion; Dose Expansion; Dose Expansion
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.